Argent Trust Co Purchases 2,125 Shares of Zoetis Inc. (NYSE:ZTS)

Argent Trust Co boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 10.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,902 shares of the company’s stock after acquiring an additional 2,125 shares during the quarter. Argent Trust Co’s holdings in Zoetis were worth $3,970,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Webster Bank N. A. lifted its position in Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the last quarter. Neo Ivy Capital Management acquired a new position in shares of Zoetis during the fourth quarter worth approximately $40,000. LRI Investments LLC acquired a new stake in shares of Zoetis in the first quarter worth $43,000. Hazlett Burt & Watson Inc. increased its position in Zoetis by 60.7% during the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after acquiring an additional 102 shares during the period. Finally, Central Valley Advisors LLC acquired a new position in Zoetis during the 2nd quarter valued at $49,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $200.00 target price on shares of Zoetis in a research note on Tuesday, August 27th. BTIG Research boosted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $217.11.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $195.74 on Wednesday. The business has a fifty day moving average of $183.65 and a 200-day moving average of $174.15. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The firm has a market cap of $88.68 billion, a PE ratio of 37.71, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter last year, the company posted $1.41 EPS. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. On average, equities research analysts predict that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.